MedTrace Logo

Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

NCT00064025 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2016-04-11

Study results available
· View outcomes & findings →

Summary

This phase II trial is studying how well medroxyprogesterone works in treating patients with endometrioid adenocarcinoma (cancer) of the uterine corpus (the body of the uterus, not including the cervix). Hormone therapy using medroxyprogesterone may be effective in treating endometrioid cancer.

Conditions

  • Endometrial Adenocarcinoma
  • Endometrial Adenosquamous Carcinoma
  • Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
  • Recurrent Uterine Corpus Carcinoma
  • Stage I Uterine Corpus Cancer
  • Stage II Uterine Corpus Cancer
  • Stage III Uterine Corpus Cancer
  • Stage IV Uterine Corpus Cancer

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Medroxyprogesterone

Given IM

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgical hysterectomy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Gynecologic Oncology Group

    lead NETWORK

Principal Investigators

  • Richard Zaino · Gynecologic Oncology Group

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00064025 on ClinicalTrials.gov